文献速递乳腺MR

ER+/HER2-乳腺癌患者新辅助内分泌治疗前及治疗中乳腺MRI特征对术前内分泌预后指数的预后价值

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer.
PubMed 文献 · Br J Radiol · 2021-01-01

该回顾性观察性队列研究纳入35例ER+/HER2-乳腺癌患者的38个肿瘤,分析新辅助内分泌治疗前及治疗3个月时MRI的BIRADS特征与术前内分泌预后指数(PEPI)的关系。结果显示仅治疗3个月时肿瘤体积缩小较大与PEPI-1(预后良好)相关,PEPI-1肿瘤缩小10 mm(IQI: 5, 13.5)vs PEPI-2/3肿瘤缩小4.5 mm(IQI: 3, 7;p = .045),其他BIRADS特征、退缩模式及影像学缓解均与PEPI无关。

要点

  • 新辅助内分泌治疗3个月时MRI肿瘤缩小越大与PEPI-1预后良好相关。
  • 既往在新辅助化疗中与预后相关的MRI特征在内分泌治疗中不一定相关。
  • 治疗前BIRADS特征、退缩模式和影像学缓解均与PEPI无显著关联。

核心结论

  • 仅新辅助内分泌治疗3个月时MRI上肿瘤体积缩小较大与ER+/HER2-乳腺癌PEPI-1(预后良好)相关。
  • 其他BIRADS特征、退缩模式或影像学缓解与PEPI无显著关联。
  • 既往报道在新辅助化疗期间与预后相关的MRI特征,在ER+/HER2-乳腺癌新辅助内分泌治疗中不一定与预后相关。

研究设计与样本

  • 回顾性观察性队列研究,纳入35例ER+/HER2-乳腺癌患者的38个肿瘤(3例双侧),均接受新辅助内分泌治疗。
  • 治疗前及治疗3个月时MRI由两位乳腺放射科医生评估BIRADS影像特征、退缩模式和影像学缓解。
  • 终点为术前内分泌预后指数(PEPI),基于术后手术标本的pT和pN分期、Ki67及ER状态计算。
  • 肿瘤分为PEPI-1(预后良好)或PEPI-2/3(预后不良)。

诊断标准与关键数值

  • PEPI-1为预后良好,PEPI-2/3为预后不良;PEPI基于术后手术标本的pT和pN分期、Ki67及ER状态。
  • 治疗3个月时肿瘤缩小:PEPI-1肿瘤10 mm(IQI: 5, 13.5)vs PEPI-2/3肿瘤4.5 mm(IQI: 3, 7),p = .045。
  • 17个肿瘤(44.7%)为PEPI-1,21个肿瘤(55.3%)为PEPI-2/3。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate whether BIRADS MRI characteristics before or during neoadjuvant endocrine therapy (NET) are associated with the preoperative endocrine prognostic index (PEPI) in ER+/HER2- breast cancer patients.

METHODS: This retrospective observational cohort study included 35 ER+/HER2- patients with 38 tumors (3 bilateral cases) treated with NET. The pre- and midtreatment (after 3 months) MRIs were evaluated by two breast radiologists for BIRADS imaging characteristics, shrinkage pattern, and radiologic response. PEPI was used as end point. PEPI is based on the post-treatment surgical specimen's pT- and pN-stage, Ki67, and ER-status. Tumors were assigned PEPI-1 (good prognosis) or PEPI-2/3 (poor prognosis). We investigated whether pre- and midtreatment BIRADS characteristics were associated with PEPI.

RESULTS: Median patient age was 65 years (interquartile interval [IQI]: 53, 70). 17 tumors (44.7%) were associated with good prognosis (PEPI-1), and 21 tumors (55.3%) with poor prognosis (PEPI-2/3). A larger reduction in tumor size after 3 months of NET was significantly associated with PEPI; 10 mm (IQI: 5, 13.5) in PEPI-1 tumors vs 4.5 mm (IQI: 3, 7; p = .045) in PEPI-2/3 tumors. Other BIRADS characteristics, shrinkage pattern or radiologic response were not associated with PEPI.

CONCLUSION: Only a larger reduction in tumor size on MRI after 3 months of NET was associated with PEPI-1 (good prognosis) in ER+/HER2- breast cancer patients.

ADVANCES IN KNOWLEDGE: MRI characteristics previously reported to be associated with prognosis during neoadjuvant chemotherapy are not necessarily associated with prognosis during NET in ER+/HER2- breast cancer patients.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Ragusi MA, Winter-Warnars GA, Wesseling J, et al. Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer. Br J Radiol. 2021. PMID: 34142870. doi:10.1259/bjr.20201125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。